[6] In the MSLT - 1 trial, patients with isolated nodal recurrence had more total lymph nodes
involved by melanoma than patients randomized to SLN biopsy who had a positive biopsy (all of whom were to have CLND; an average of 3.2 lymph nodes involved with metastatic melanoma vs only 1.4 positive nodes, respectively; P <.0001), [2] and were more likely to meet established criteria for adjuvant radiation, [7] which further increases the risk of postoperative lymphedema.
Not exact matches
In one experiment this year, a team led
by another CRISPR pioneer, Feng Zhang of the Broad Institute in Cambridge, Massachusetts, targeted the 20,000 or so known human genes, turning them on one
by one in groups of cells to identify those
involved in resistance to a
melanoma drug.
Right now, the UPV / EHU researchers are in the phase
involving the validation of candidate genes
by analyzing their expression levels in biopsies of
melanoma and nevi (growths of non-malignant melanocytes).
The only previous trial of this approach, conducted
by Dr. Gary Nabel and colleagues at the University of Michigan,
involved five patients with metastatic
melanoma, a lethal skin cancer.
A research team led
by Gianluca Maddalo (KTH),
involving several researchers at SciLifeLab, has discovered that
melanoma resistance against BRAF and Hsp90 inhibitors can be overcome
by implementing the current BRAF / MEK inhibitors therapy with a CDK2 inhibitor, dinaciclib, already used in clinical trials.
Her work
involves lymphoma,
melanoma, mammary and other types of cancer and canine tumors, and it has been funded several times
by the American Kennel Club and the National Institutes for Health.